Porton Advanced is introducing a new CRISPR gene editing service for stable cell line construction and stable cell line engineering. Our new CRISPR editing technology will provide customers with fast, accurate, and integrated technical services. We offer customized editing solutions suitable for various cell lines, while also supporting diverse delivery methods such as RNP, lentivirus, plasmids, and multiple detection methods for basic research, antibody validation, drug candidate screen, disease diagnosis, and etc.
Porton Advanced has built CRISPR, a gene editing platform with proven results. We are able to formulate CRISPR based methodologies by implementing gene editing techniques including knock-in/knock-out in varying cell lines as per client request. The knock-in efficiency can be over 40%, while the knock-out efficiency can be over 98%.
Our experts have extensive experience and a deep understanding in viral transfection/non-viral electroporation systems. By making continuous efforts in optimizing the procedures, our team guarantees a high-efficient and stable transfection/electroporation system with high cell viability.
For certain targets, our experts use dual test efficiency at the nucleic acid and protein levels to assess gene editing efficiency, whereas cell viability assay is used for deliverables control. Our testing services fully assess gene editing efficiency by conducting testing from aspects of cell characteristics, gene expression regulation, and cell function.
Our project management can customize experimental plans with optional deliverables and routinely report project progress, per client request.